Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of “Hold” by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have received an average recommendation of “Hold” from the fifteen research firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.10.

IOVA has been the subject of a number of analyst reports. Barclays boosted their price objective on Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Iovance Biotherapeutics in a report on Wednesday, October 8th. Chardan Capital cut their price objective on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Finally, HC Wainwright decreased their target price on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, October 29th.

Iovance Biotherapeutics Price Performance

NASDAQ IOVA opened at $2.52 on Thursday. The company has a market cap of $1.00 billion, a P/E ratio of -2.10 and a beta of 0.83. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $8.15. The company has a 50-day moving average of $2.25 and a 200-day moving average of $2.26.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $67.46 million for the quarter, compared to analyst estimates of $76.20 million. Iovance Biotherapeutics had a negative net margin of 158.78% and a negative return on equity of 55.24%. As a group, equities research analysts anticipate that Iovance Biotherapeutics will post -1.24 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in Iovance Biotherapeutics during the 3rd quarter valued at $26,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Iovance Biotherapeutics during the third quarter worth $27,000. WealthTrust Axiom LLC grew its stake in shares of Iovance Biotherapeutics by 80.0% during the second quarter. WealthTrust Axiom LLC now owns 18,000 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 8,000 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Iovance Biotherapeutics by 67.6% during the third quarter. Federated Hermes Inc. now owns 15,111 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 6,095 shares during the last quarter. Finally, Wealthfront Advisers LLC acquired a new position in Iovance Biotherapeutics in the third quarter valued at approximately $34,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.